The National Institute for Health and Care Excellence has published guidance on high-sensitivity troponin tests for early rule out of non-ST-segment elevation myocardial infarction (NSTEMI), recommending assays such as Beckman Coulter’s Access hsTnI.
Combining a high-sensitive troponin assay with a rapid rule-out protocol quickly indicates if a person has a myocardial infarction or not. Therefore, the hsTnI helps both the patient and the hospital, leading to reduced waiting times for patients, while also allowing hospitals to deliver safe, high-quality urgent and emergency care.
National Institute for Health and Care Excellence (NICE) guidance also references the 2020 European Society of Cardiology (ESC) guidance, where high-sensitivity cardiac troponin tests with validated 0/1 h and 0/2 h algorithms are now cited as a Class I recommendation for diagnosis using rapid ‘rule-in’ and ‘rule-out’ algorithms. Beckman Coulter’s Access hsTnI I is listed with assay-specific cut-offs for both 0/1 h and 0/2 h algorithms, delivering reliable results that clinicians can use with confidence to make decisions about patient management.